| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| - | - | 4,200 | ₹3.25 -51.85% | 3,375-38.63% |
| - | - | 4,400 | ₹9.2 -33.57% | 2,37572.72% |
| - | - | 4,500 | ₹13.9 -42.08% | 13,0000.97% |
| - | - | 4,600 | ₹26.5 -27.79% | 10,0009.58% |
| 3750% | ₹260 0% | 4,700 | ₹43.1 -29.34% | 22,37544.35% |
| 250100% | ₹230.2 25.79% | 4,750 | - | - |
| 18,250-3.94% | ₹200.85 12.99% | 4,800 | ₹70 -24.65% | 34,25014.64% |
| 5,25016.66% | ₹171.65 15.94% | 4,850 | ₹87.9 -25.25% | 2,50025% |
| 29,8756.22% | ₹146.85 18.47% | 4,900 | ₹108.15 -24.23% | 17,75067.05% |
| 1,3750% | ₹118.7 0% | 4,950 | - | - |
| 49,7507.56% | ₹100.95 21.69% | 5,000 | ₹161.55 -19.94% | 26,0007.21% |
| 3,8750% | ₹79.65 0% | 5,050 | - | - |
| 36,125191.91% | ₹62.4 14.18% | 5,100 | ₹228.2 -13.96% | 6,12525.64% |
| - | - | 5,150 | - | - |
| 23,250161.97% | ₹38.7 10.72% | 5,200 | - | - |
| 3,750-30.23% | ₹23.25 -13.88% | 5,300 | ₹470 0% | 3750% |
| 3,625123.07% | ₹14.2 -32.05% | 5,400 | ₹488.6 -6.03% | 250100% |
| 4,87577.27% | ₹8.2 -15.89% | 5,500 | - | - |
| 1250% | ₹7.4 0% | 5,550 | - | - |
| 1250% | ₹4.6 0% | 5,600 | - | - |
| 6,3750% | ₹3.8 0% | 5,700 | - | - |
| 8,1250% | ₹3 0% | 5,800 | ₹955 0% | 2500% |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
